INmune Bio Inc. Enters $19 Million Registered Direct Offering
INmune Bio Inc. (NASDAQ: INMB), a clinical-stage company focused on inflammation and immunology, has made headlines with a new venture to secure substantial funding. The company announced its agreement to proceed with a registered direct offering, encompassing 3 million shares of common stock priced at $6.30 each. This move aligns with Nasdaq regulations, giving investors an opportunistic entry point into the company’s journey.
Details of the Offering
The upcoming offering is expected to close shortly, pending compliance with standard closing requirements. With projected gross proceeds around $19 million, the funds will play a vital role in supporting INmune’s operational and developmental needs. The company aims to channel these resources toward working capital and general corporate functions, optimizing its strategy for upcoming clinical trials.
Collaboration with A.G.P./Alliance Global Partners
INmune Bio's partnership with A.G.P./Alliance Global Partners as the sole placement agent underlines the significance of this offering. The choice of a reputed financial partner not only reinforces investor confidence but also enhances the visibility of INmune's groundbreaking research and development initiatives.
Regulatory Framework and Future Outlook
This offering is executed under an already effective shelf registration statement filed with the U.S. SEC, demonstrating INmune’s proactive stance within regulatory frameworks. A related prospectus will soon become accessible via the SEC’s platform. Such transparency is essential for existing and potential investors, reiterating INmune’s commitment to adhering with all compliance requirements.
Understanding INmune's Innovative Product Platforms
INmune Bio is at the forefront of medical innovation, specifically in developing treatments targeting the innate immune system to address severe health conditions. Their product pipeline includes:
1. Dominant-Negative Tumor Necrosis Factor (DN-TNF)
This platform is centered around a technology that neutralizes soluble TNF, which is a significant driver of immune dysfunction. Rigorous clinical trials are underway to evaluate its efficacy in treating Mild Alzheimer’s disease, Mild Cognitive Impairment, and treatment-resistant depression.
2. Natural Killer Cell Priming Platform
Features INKmune®, a pioneering approach designed to mobilize a patient's NK cells. This initiative aims to eliminate residual cancerous cells, currently undergoing trials in areas such as metastatic castration-resistant prostate cancer.
3. CORDStrom™ Technology
This innovative approach involves human umbilical cord-derived mesenchymal stem cells. It has recently completed successful clinical trials concerning recessive dystrophic epidermolysis bullosa, adding to INmune’s reputation for tackling complex medical conditions.
Company Vision and Commitment
INmune Bio’s mission centers on meeting the unmet medical needs through groundbreaking therapies that employ precision medicine strategies. With a portfolio addressing chronic inflammation and cancer, the company remains dedicated to enhancing patient outcomes through scientific excellence.
Company Contact Information
For those seeking more information, key personnel include:
David Moss, Chief Financial Officer
(561) 710-0512
info@inmunebio.com
Daniel Carlson, Head of Investor Relations
(415) 509-4590
dcarlson@inmunebio.com
Frequently Asked Questions
What is the main purpose of INmune Bio's $19 million offering?
The funding aims to support working capital and general corporate needs, enhancing clinical trial endeavors.
Who is acting as the placement agent for this offering?
A.G.P./Alliance Global Partners is the sole placement agent for the registered direct offering.
What products are being developed by INmune Bio?
INmune is developing treatments targeting chronic inflammation and cancer through innovative platforms like DN-TNF, INKmune®, and CORDStrom™.
How does INmune ensure compliance with SEC regulations?
INmune conducts its offerings through effective shelf registration statements, keeping investors informed and compliant with regulations.
How can investors contact INmune Bio for more information?
Investors can reach David Moss, CFO, or Daniel Carlson, Head of Investor Relations, through the provided contact details via email or phone.
